Todd Michael Cooper, DO


On staff since February 2015

Children's Title: Co-Interim Division Chief, Hematology-Oncology; Evans Family Endowed Chair in Pediatric Cancer

Research Center: Center for Clinical and Translational Research

  • Todd M. Cooper, DO, is an attending physician at Seattle Children's Hospital and an Associate Professor of Pediatrics at the University of Washington School of Medicine. Dr. Cooper is the Director of the Pediatric Leukemia/Lymphoma Program.

    Dr. Todd Coopers interests and expertise focus on the development of new therapeutic strategies for the treatment of acute leukemia in children. He completed his fellowship training at the University of Texas MD Anderson Cancer Center, where he became well versed in the testing novel therapies for treating children with high-risk malignancies.

    Dr. Cooper developed and provided leadership for Phase I/Developmental Therapeutics Programs at the University of Alabama at Birmingham and Children's Healthcare of Atlanta/Emory University. During that time, Dr. Cooper led Phase I trials of new agents for relapsed acute leukemia in a variety of national consortia. He currently serves as the chair of the COG Acute Myeloid Leukemia(AML)New Agents Committee and actively collaborates internationally to help maintain a cohesive strategy for the treatment of children with acute leukemia. Currently, Dr. Cooper is developing the next national, randomized Phase III COG trial for children with newly diagnosed AML as well as the COG Phase II trial for relapsed AML.

    Dr. Cooper is dedicated to offering hope to children with complex hematologic malignancies by providing access to the most promising and innovative therapies.

    • Hilda Atlanta, GA 01.14.20

      Doctor Cooper is the best !! I’m thankful to God for this wonderful doctor in my journey’s son. I always praying for him. God bless.

    • Kadee San Diego, CA 10.29.17

      While living in Bothell, WA we had the privilege of having Dr Cooper as our son’s doctor. He provided a sense of calm and peace during a very trying time. His bedside manner and knowledge was unsurpassed. We have since left the area and miss Dr Cooper very much. No one will ever measure up.

  • Other Publications

    • Tarlock K, Chang B, Cooper T, Gross T, Gupta S, Neudorf S, Adlard K, Ho PA, McGoldrick S, Watt T, Templeman T, Sisler I, Garee A, Thomson B, Woolfrey A, Estey E, Meshinchi S, Pollard JA
      Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
      25662999 Pediatric blood & cancer, 2015 Feb. 8
    • Niemeyer CM, Loh ML, Cseh A, Cooper T, Dvorak CC, Chan R, Xicoy B, Germing U, Kojima S, Manabe A, Dworzak M, De Moerloose B, Starý J, Smith OP, Masetti R, Catala A, Bergstraesser E, Ussowicz M, Fabri O, Baruchel A, Cavé H, Zwaan M, Locatelli F, Hasle H, van den Heuvel-Eibrink MM, Flotho C, Yoshimi A
      Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.
      25552679 Haematologica, 2015 Jan. : 100(1)17-22 PMCID:PMC4281308
    • Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI
      AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
      24771494 Cancer, 2014 Aug. 15 : 120(16)2482-9 PMCID:PMC4126862
    • Faulk K, Gore L, Cooper T
      Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.
      24639021 Paediatric drugs, 2014 June : 16(3)213-27
    • Stieglitz E, Liu YL, Emanuel PD, Castleberry RP, Cooper TM, Shannon KM, Loh ML
      Mutations in GATA2 are rare in juvenile myelomonocytic leukemia.
      24578498 Blood, 2014 Feb. 27 : 123(9)1426-7 PMCID:PMC3938154
    • Cooper TM, Razzouk BI, Gerbing R, Alonzo TA, Adlard K, Raetz E, Gamis AS, Perentesis J, Whitlock JA
      Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
      23335239 Pediatric blood & cancer, 2013 July : 60(7)1141-7
    • Jayanthan A, Cooper TM, Hoeksema KA, Lotfi S, Woldum E, Lewis VA, Narendran A
      Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.
      23176524 Leukemia & lymphoma, 2013 July : 54(7)1505-16
    • Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG, Borowitz MJ, Kadota R, Cooper T, Shen V, Dahl G, Thottassery JV, Jeha S, Maloney K, Paul JA, Barry E, Carroll WL, Gaynon PS
      Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
      21967976 Blood, 2011 Dec. 1 : 118(23)6043-9 PMCID:PMC3731655
    • Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML
      Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.
      18954903 Leukemia research, 2009 March : 33(3)355-62 PMCID:PMC2692866
    • Cooper T, Ayres M, Nowak B, Gandhi V
      Biochemical modulation of cytarabine triphosphate by clofarabine.
      15723262 Cancer chemotherapy and pharmacology, 2005 April : 55(4)361-8


Board Certification(s)

Pediatric Hematology-Oncology

Medical/Professional School

Nova Southeastern University Osteopathic Medicine, Fort Lauderdale


Pediatrics, University of South Alabama, Mobile


Pediatric Hematology Oncology, UT MD Anderson Cancer Center, Houston

Research Focus Area

Cancer biology